Confronto
Abaloparatid vs. Icatibant
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
247062-33-5
138614-30-9
Peso molecolare
3960.6 g/mol
1304.52 g/mol
Emivita
1.7 h
nessun dato
Sequenza
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2nessun dato
Meccanismo d'azione
Abaloparatid
Abaloparatide is a synthetic analogue of the first 34 amino acids of parathyroid hormone-related protein (PTHrP). Like parathyroid hormone and teriparatide it binds the PTH-1 receptor, but the literature describes it as preferentially engaging the so-called RG conformation of the receptor, which is associated with shorter signaling duration. As for the entire drug class, intermittent receptor activation is regarded as the mechanistic basis for the stimulation of bone-forming osteoblasts observed in studies, whereas continuously elevated exposure would tend to favor bone resorption. From this binding behavior the literature derives a discussed balance between bone formation and bone resorption.
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
4
1
Contraddizioni aperte
1
0
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Abaloparatid and Icatibant?
- Abaloparatid is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". Abaloparatid: Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Abaloparatid or Icatibant?
- The highest available evidence level is "RCT sull'uomo" for Abaloparatid and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Abaloparatid and Icatibant in Germany and the United States?
- Germania: Abaloparatid — Su prescrizione, Icatibant — Su prescrizione. Stati Uniti: Abaloparatid — Su prescrizione, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.